* Kodiak Sciences Inc KOD.OQ KOD.O is expected to show
no
change in quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for Kodiak Sciences Inc
is
for a loss of $1.21 per share.
* The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Kodiak
Sciences
Inc is $4, above its last closing price of $2.11.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 -1.00 -1.14 -1.53 Missed -34.1
Mar. 31 2023 -1.21 -1.33 -1.35 Missed -1.8
Dec. 31 2022 -1.53 -1.35 Beat 11.5
Sep. 30 2022 -1.77 -1.77 -1.47 Beat 16.9
Jun. -1.76 -1.76 -1.74 Beat 0.9
30 2022
Mar. 31 2022 -1.57 -1.54 -1.83 Missed -19
Dec. 31 2021 -1.36 -1.36 -1.79 Missed -31.5
Sep. 30 2021 -1.17 -1.16 -1.30 Missed -12.1
This summary was machine generated November 3 at 11:55 GMT. All
figures in US dollars unless otherwise stated